ALBERT NGUYEN: Open Payments
NPI 1992124986 · SAN BERNARDINO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$776 in 27 payments from 10 companies in 2025. Trend: 2023 $786 · 2024 $1,382 · 2025 $776
Food & beverage: $776
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 5 | $159 |
| E.R. Squibb & Sons, L.L.C. | 3 | $148 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
| Alkermes, Inc. | 3 | $61 |
| Janssen Pharmaceuticals, Inc | 3 | $52 |
| ABBVIE INC. | 3 | $51 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| Vanda Pharmaceuticals Inc. | 2 | $35 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $28 |
Products named: INGREZZA, COBENFY, Auvelity, REXULTI, ARISTADA, VRAYLAR, AUSTEDO XR, FANAPT.
Industry payments across CA — which companies pay providers there.
